Keyword Search Year None202120202019201820172016201520142013201220112010200920082007200620052004200320022001 11/24/21 Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference 11/19/21 Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors 11/11/21 Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders 11/09/21 Alkermes to Take Part in the Stifel Virtual Healthcare Conference 11/08/21 Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica 11/03/21 Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting 10/29/21 Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences 10/27/21 Alkermes plc Reports Third Quarter 2021 Financial Results 10/26/21 Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer 10/25/21 Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer 10/20/21 Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021 10/18/21 Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder 09/22/21 Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference 09/22/21 New Survey Provides Insights Into Drinking Behaviors During the Pandemic 09/13/21 Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress 09/09/21 Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program 09/02/21 Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference 08/02/21 Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma 07/28/21 Alkermes plc Reports Second Quarter 2021 Financial Results 07/23/21 Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program 07/21/21 Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021 06/30/21 Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence 06/22/21 Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign 06/04/21 Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting 06/03/21 Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference 06/01/21 Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder 05/28/21 Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting 05/20/21 Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors 05/13/21 Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer 05/05/21 Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference 05/03/21 Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month 04/30/21 Alkermes Announces Agreement with Sarissa Capital 04/28/21 Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting 04/28/21 Alkermes plc Reports First Quarter 2021 Financial Results 04/27/21 Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence 04/27/21 Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma 04/21/21 Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results 04/20/21 Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society 04/07/21 Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer 03/25/21 Alkermes to Take Part in Stifel's 3rd Annual CNS Day 03/25/21 Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy 03/11/21 Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma 03/04/21 Alkermes to Hold Virtual Investor Day 02/18/21 Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference 02/11/21 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021 02/04/21 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results 01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine 01/06/21 Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference 01/06/21 Alkermes Announces Updates to Executive Leadership Team
11/19/21 Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
11/11/21 Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
11/03/21 Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
10/29/21 Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences
10/26/21 Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
10/25/21 Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
10/18/21 Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
09/13/21 Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress
08/02/21 Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
06/30/21 Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence
06/22/21 Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign
06/04/21 Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
06/01/21 Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
05/28/21 Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
05/13/21 Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
05/03/21 Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
04/28/21 Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
04/27/21 Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
04/20/21 Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
04/07/21 Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
03/11/21 Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
02/11/21 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
02/04/21 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
